If some modification of the chemical structure of L-thyroxin or L-triiodothyronine resulted in an analogue that largely retained the effect of the natural hormones on cholesterol metabolism but was sufficiently less active in its other metabolic effects, a way out of this dilemma would be available.
DRIED THYROID SUBSTANCE or the pure natural hormoues, L-thyroxin and L-triiodothyronine, effect a reduction in the serum total cholesterol of euthyroid individuals when administered in sufficient allmount.1-3 Their general clinical use to reduce elevated serum cholesterol levels in the hope of favorably influencing the course of atherosclerosis has been limited by two factors. When given in moderate dosage, dried thyroid substance effected a prompt reduction in serum cholesterol, but despite continuation of the hormone the reduction was not sustained. 4 This "escape" is presumed to be due to suppression of thyrotropin secretion byr the administered thyroid and consequent decrease in production of endogenous thyroid hormone. When the dose of administered hormone is increased to maintain a reduced serum cholesterol level, hypermetabolisnm manifested by an increased basal metabolic rate, tachycardia, and weight loss may occur. An ominous consequence of thyroid hormone administration to patients with coronary artery disease is the frequent inerease in severity of angina pectoris. 5 If some modification of the chemical structure of L-thyroxin or L-triiodothyronine resulted in an analogue that largely retained the effect of the natural hormones on cholesterol metabolism but was sufficiently less active in its other metabolic effects, a way out of this dilemma would be available.
In the rat the formic acid analogue of thyroxin, tetraiodothyroforinic acid, has been Supported by research grant H-1946 from the National Heart Institute, U. S. Public Health Service, and the Kentucky Heart Association.
Presented at the meeting of the Council on Arteriosclerosis, The American Heart Association, St. Louis, Missouri, October 21, 1960. shown to exert an effect oli cholesterol metabolism that is disproportionate to its effect on oxygen consumption, growth, and thiouracil-induced goiter."-8 More recent studies in the rat of a series of thyroxin analogues have shown that the D-isomers of thyroxin and triiodothyronine also exert a disproportionate effect on cholesterol metabolism.9
In view of these observations in the experimental animal that replacement of the Thyroid hormones and analogues studied in the human subject. The goiter-inhibiting activities, with L-thyroxin assigned a value of 100, are those determined in our laboratory. The daily dose is that given the euthyroid patients.
and consumed a fairly constant diet; the remaining patients were seen as outpatients and continued their usual diets. All patients were seen at 2-or 3-week intervals, the visits being scheduled at approximately the same time of day. After a 20-minute rest period the pulse rate and body weight were recorded, blood was drawn, and the clinical state of the patient was evaluated. Serum total cholesterol was determined by the method of Abell et al. 10 The L-thyroxin and analogues were given orally, in single or twice daily doses. The total daily dose of each hormone is indicated in figure 1 . During the periods immediately preceding and following those of drug administration the patients received placebos that were identical in appearance to the active drug. Whenever a change in the appearance of the medication or the frequency of administration was necessitated by the form available, it was accomplished during the placebo period.
Thirty-four treatment periods of 6 weeks to 10 months were completed in the 17 patients, each being preceded and followed by a period of placebo administration. Five patients received only one drug, the other patients two to four.
Seven myxedematous patients were also observed for periods ranging up to 5 years. Six Circulation, Volume XXIV, July 1951 were female and one male; ages ranged from 37 to 74 years, with a mean of 55 years. In three the etiology of the myxedema was unknown; in the remaining four it was the result of thyroid surgery or therapeutic radioiodine. Prior to treatment basal metabolic rates ranged from minus 39 to minus 18 per cent, serum protein-bound iodine from 0.5 to 1.7 pg. per 100 ml., and serum total cholesterol from 260 to 450 mg. per 100 ml.
After the diagnosis of myxedema was established and replacement therapy was instituted with L-thyroxin or L-triiodothyronine, the patients were observed as described for the euthyroid subjects. In The mean control serum cholesterol of patients receiving dimethyl-TFA-2 was 284 mg. per 100 ml. Responses to drug and placebo administration are indicated as in figure 2.
Patients a to 7, 11, 13, and 16. was 294 mg. per 100 ml., the mean level during the 4-to 8-month treatment period was 219, a reduction of 26 per cent. Again the serum cholesterol returned to the pretreatinent range following the substitution of a placebo.
Eight patients received D-triiodothyronine (D-T3) for periods of 3 to 10 months (fig. 5 ). The administration of 0.5 mg. of D-T3 twice daily resulted in a fall in mean serum cholesterol from 294 to 225 mg. per 100 ml., the reduction in the individual patients ranging from 42 to 94 mg. per 100 ml. In the six patients in whom a placebo had been substituted for the D-T3 at the time of this report, a return of the serum cholesterol to the control range occurred within 6 weeks.
Circulation, Volume XXIV, July 1961 The mean control serum cholesterol of the seven patients receiving L-thyroxin (L-T4) was 312 mg. per 100 ml. (fig. 6 ). Although the response of the individual patients was somewhat more variable than that to the analogues, the mean reduction of 15 per cent of the control level is not appreciably different from that resulting from the formic acid analogues ( fig. 7) . No tendency to escape from this effect was observed during the mean treatment period of 71/2 months; substitution of placebo again resulted in a prompt return to the pretreatment range.
Undesirable side effects occurred in several of the patients while they were receiving the formic acid analogues. Diarrhea and cramping abdominal pain were experienced by two Serum Cholesterol +15%1, +5%.
-5% -'5% -25%°2 The mean control serum cholesterol of patients receiving D-T4 was 294 mg. per 100 ml. Responses to drug and placebo administration are indicated as in figure 2 Figure 5 The mean control serum cholesterol of patients receiving D-T3 was 294 mg. per 100 ml. Responses to drug and placebo administration are indicated as in figure 2 . Patients 1, 3, 4, 7, 9 to 11, and 15.
( fig. 8 ). Each analogue was tolerated by the patients with myxedema without the development of angina or other undesirable effects in doses equal to or exceeding those employed in the euthyroid subjects.
Discussion
Each of the four analogues studied, TFA-4, dimethyl-TFA-2, D-T4, and D-T3, resulted in a mean reduction of serum total cholesterol of the euthyroid patients. Although the subjects displayed the usual variability in serum cholesterol during both control and treatment periods, the consistency with which the mean level during treatment was reduced and the return to the pretreatment range when a placebo was substituted would seem to elimiCirculation, Volume XXIV, July 1961 nate the possibility that these changes in serum cholesterol levels were due to spontaneous fluctuation.
The The mean control serum cholesterol of patients receiving L-T4 waas 312 mg. per 100 ml. Responses to drug and placebo administration are indicated as in figure 2 . Patients 1 to 3, 5, 13, 14, and 17.
the maintenance of reduced serum cholesterol levels throughout the period of its administration to euthyroid subjects has been noted by Starr et al.1' and by Jones.12 In view of the presumed mechanism of this escape phenomenon, its failure to occur with these analogues may be due to their relatively lesser inhibition of thyrotropin secretion.9
The analogues, unlike L-T4, did not induce or aggravate symptoms in any of the 14 patients with arteriosclerotic heart disease. None developed or experienced intensificaton of angina pectoris or congestive heart failure during therapy with the analogues. One patient did have a recurrent myocardial infarction during the placebo period after treatment. Boyd and Oliver13 also observed no intensificationI of angina with a 10-img. daily dose of D-T4, but unlike our experience they did observe an increase in angina with D-T3 at a daily dose of 1 mg. It is noteworthy that in their study about one half of the patients who experienced intensification of angina pectoris during administration of various thyrominetic compounds displayed no concomitant increase in basal metabolic rate.
Attempts early in our study to evaluate any possible effects of the analogues on basal metabolic rate of the euthyroid patients were abandoned, the variability of repeated determinations, even in the hospitalized patients, being sufficient to obscure any moderate change. The lack of effect of the analogues on resting pulse rate and body weight suggests that they A possible explanation for the disproportionate effect of these dextro isomers of thyroxin and triiodothyronine on cholesterol metabolism is offered by the recent observation of differences in their tissue distribution as compared to the L-isomers. The D-isomers were found in a relatively higher concentration in the liver than in skeletal and cardiac muscle as compared to the natural hormones.i4, 15 In view of the dominant role of the liver in the regulation of plasma cholesterol, the disproportionate effect on serum cholesterol of the D-isomers may be attributable to their relatively higher concentration in this organ. Summary li-thyroxin and four thyroxin analogues were administered to a group of hypercholesteremic euthyroid patients, the majority with arteriosclerotic heart disease, and the effects on serum total cholesterol compared. L-thyroxin and each of the analogues studied, tetraiodothyroformic acid, dimethyldiiodothyroformic acid, D-thyroxin and D-triiodothyronine, were given to four to nine patients for periods up to 10 months.
At the doses employed each of the analogues resulted in a reduction in the mean level of serum cholesterol without obvious evidence of hypermetabolism or aggravation of angina pectoris or congestive heart failure. The reduced level of serum cholesterol was sustained throughout the period of hormone administration, and upon the substitution of a placebo returned to the pretreatment range.
L-thyroxin, at the dose employed, also effected a modest sustained reduction in serum cholesterol but both patients with angina included in this group experienced an increase in severity of symptoms.
Except for four patients who developed acneiform dermatitis, salivary gland swelling, or gastrointestinal symptoms during the administration of the formic acid analogues, no toxic or undesirable effects were observed from any of the analogues.
To evaluate better the general metabolic effects of the analogues each was administered to three or more of a group of seven myxedematous patients for periods of 6 to 12 months. Given in sufficient amount all were observed to increase basal metabolic rate and to maintain a clinically euthyroid state.
From these observations, it is concluded that the D-isomers of thyroxin and triiodothyronine, while not without general metabolic effects, are tolerated by the majority of euthyroid patients with coronary atherosclerosis in amounts sufficient to maintain a reduced serum cholesterol level.
